{"schema_version":"secwatch.filing_event.v1","accession":"0000819050-23-000057","form_type":"8-K","ticker":null,"cik":"0000819050","company_name":"Fresh Tracks Therapeutics, Inc.","filed_at":"2023-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.724068+00:00","generated_at":"2026-06-13T03:42:21.594592+00:00","sec_items":["5.02","5.03","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Director Robert Brown resigns from Fresh Tracks board; board reduced to 3 members; Nasdaq compliance regained","bullets":["Robert B. Brown resigned from the Board effective July 24, 2023; no disagreement with operations or policies.","Board reduced minimum number of directors from 4 to 3 via amended bylaws, and reduced board size to 3.","Company regained Nasdaq compliance for independent director and audit committee requirements under Rule 5605."],"urls":{"canonical":"https://secwatch.observer/filing/0000819050-23-000057","json":"https://secwatch.observer/filing/0000819050-23-000057.json","markdown":"https://secwatch.observer/filing/0000819050-23-000057.md","text":"https://secwatch.observer/filing/0000819050-23-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/819050/000081905023000057/0000819050-23-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/819050/000081905023000057/frtx-20230724.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T03:42:21.594592+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"72317c67e4","claim":"Robert B. Brown resigned as Director at Fresh Tracks Therapeutics, Inc..","evidence_excerpt":"On July 24, 2023, Robert B. Brown informed Fresh Tracks Therapeutics, Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”), effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/819050/000081905023000057/0000819050-23-000057-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c73556fc080666e39893e4b24795e937291d0acc","claim":"Fresh Tracks Therapeutics, Inc.: Board adopted Amended and Restated Bylaws to reduce the minimum number of directors from four to three, and subsequently reduced the board size accordingly (effective 2023-07-24).","evidence_excerpt":"On July 24, 2023, the Board adopted Amended and Restated Bylaws to decrease the minimum number of directors from four members to three members.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/819050/000081905023000057/0000819050-23-000057-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-07-24"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}